Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-4.97 Insider Own7.36% Shs Outstand52.51M Perf Week-14.40%
Market Cap174.86M Forward P/E- EPS next Y-4.44 Insider Trans0.00% Shs Float48.65M Perf Month-46.72%
Income-260.49M PEG- EPS next Q-1.07 Inst Own76.82% Short Float4.48% Perf Quarter-7.76%
Sales0.00M P/S- EPS this Y10.59% Inst Trans2.83% Short Ratio2.34 Perf Half Y95.88%
Book/sh5.06 P/B0.66 EPS next Y0.08% ROA-45.46% Short Interest2.18M Perf Year-35.34%
Cash/sh5.44 P/C0.61 EPS next 5Y12.40% ROE-74.22% 52W Range1.37 - 9.80 Perf YTD9.54%
Dividend Est.- P/FCF- EPS past 5Y-12.42% ROI-59.52% 52W High-66.02% Beta2.23
Dividend TTM- Quick Ratio6.93 Sales past 5Y0.00% Gross Margin- 52W Low143.07% ATR (14)0.42
Dividend Ex-Date- Current Ratio6.93 EPS Y/Y TTM22.21% Oper. Margin0.00% RSI (14)31.58 Volatility7.43% 10.21%
Employees111 Debt/Eq0.68 Sales Y/Y TTM- Profit Margin- Recom3.57 Target Price4.25
Option/ShortYes / Yes LT Debt/Eq0.65 EPS Q/Q15.79% Payout- Rel Volume0.35 Prev Close3.42
Sales Surprise- EPS Surprise-46.05% Sales Q/Q- EarningsMar 28 BMO Avg Volume933.94K Price3.33
SMA20-26.73% SMA50-36.44% SMA200-5.62% Trades Volume327,639 Change-2.63%
Date Action Analyst Rating Change Price Target Change
Dec-11-23Resumed Goldman Sell $2
Nov-17-23Upgrade CapitalOne Equal Weight → Overweight $7 → $12
Jul-27-23Downgrade UBS Buy → Neutral $15 → $4
Jul-25-23Downgrade JP Morgan Neutral → Underweight
Jul-25-23Downgrade Chardan Capital Markets Buy → Neutral
Jul-24-23Downgrade Jefferies Buy → Hold
Jul-24-23Downgrade CapitalOne Overweight → Equal Weight $7
Nov-15-22Initiated CapitalOne Overweight $24
Aug-02-22Downgrade Citigroup Neutral → Sell $6
Feb-24-22Downgrade JP Morgan Overweight → Neutral $90 → $21
Apr-04-24 12:09PM
Apr-01-24 05:04PM
Mar-29-24 10:36AM
Mar-28-24 11:53AM
08:32AM Loading…
Mar-26-24 06:15AM
Jan-30-24 06:30AM
Jan-04-24 04:15PM
Dec-14-23 11:30AM
Nov-21-23 04:15PM
Nov-15-23 08:00AM
Nov-14-23 06:09PM
05:00AM Loading…
Nov-06-23 05:00AM
Nov-01-23 11:21PM
Oct-17-23 01:44AM
Oct-11-23 06:00AM
Sep-13-23 11:30AM
Sep-08-23 06:00AM
Sep-07-23 06:00AM
Aug-16-23 10:26AM
Aug-14-23 07:31PM
Aug-02-23 10:09AM
Jul-27-23 02:30AM
Jul-26-23 06:42AM
09:16AM Loading…
Jul-25-23 09:16AM
Jul-24-23 06:26AM
Jun-14-23 11:30AM
May-30-23 04:15PM
May-16-23 07:44AM
May-15-23 04:01PM
Apr-27-23 11:30AM
Apr-21-23 07:30AM
Apr-11-23 06:29AM
Apr-04-23 01:16PM
Apr-03-23 11:38AM
Mar-28-23 04:08PM
Mar-01-23 05:55AM
Feb-09-23 07:30AM
Jan-04-23 07:00AM
Dec-09-22 11:30AM
Nov-30-22 09:55AM
Nov-16-22 04:30PM
Nov-14-22 09:55AM
Nov-10-22 02:17PM
Nov-09-22 04:01PM
Nov-02-22 06:24AM
Sep-22-22 06:06AM
Sep-08-22 11:30AM
Sep-07-22 04:05PM
Aug-26-22 01:34PM
Aug-19-22 12:32PM
Aug-18-22 05:47PM
Aug-10-22 10:57AM
Aug-09-22 04:33PM
Aug-08-22 08:39AM
Aug-05-22 04:30PM
Aug-02-22 12:07PM
Jun-12-22 09:00AM
Jun-09-22 11:30AM
May-27-22 08:00AM
May-19-22 08:00AM
May-13-22 01:44PM
May-11-22 12:38PM
May-10-22 04:10PM
May-06-22 08:50AM
Apr-29-22 05:30AM
Mar-31-22 11:30AM
Mar-23-22 06:32PM
Mar-05-22 11:07AM
Mar-04-22 05:10AM
Mar-03-22 06:21PM
Mar-02-22 10:11AM
Mar-01-22 04:05PM
Feb-25-22 10:00AM
Feb-23-22 06:00PM
Feb-07-22 05:38PM
Feb-04-22 08:30PM
Feb-03-22 05:30AM
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BORGESON JOHN A.See RemarksJun 16 '23Sale9.232,74925,373178,077Jun 16 08:25 PM
EHRLICH JASONSee RemarksJun 16 '23Sale9.232,25820,84161,924Jun 16 08:27 PM
BORGESON JOHN A.See RemarksJun 14 '23Sale9.421,44813,640175,332Jun 16 08:25 PM
EHRLICH JASONSee RemarksJun 14 '23Sale9.421,13210,66358,688Jun 16 08:27 PM